NBP 2001
Alternative Names: NBP-2001Latest Information Update: 28 Jan 2024
At a glance
- Originator SK Bioscience
- Class COVID-19 vaccines; Subunit vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention, In adults) in South Korea (IM, Injection)
- 02 Mar 2022 SK Bioscience completes a phase I trial in COVID-2019 infections (Prevention, In adults) in South Korea (IM) (NCT04760743)
- 02 Dec 2020 SK Bioscience and Seoul National University Hospital agree to co-develop NBP 2001 in South Korea for COVID-2019 infections